Navigation Links
SpectraScience Engages European Contract Research Organization to Manage Clinical Trials

SAN DIEGO, Oct. 13 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has engaged Bielderman BVBA, an experienced European contract research organization to manage the clinical process for its Barrett's esophageal cancer application under trial at certain European locations. The trial results will be used in the Company's application to the Food and Drug Administration ("FDA") for use in the United States.

Jim Hitchin, SpectraScience's CEO, commented, "The addition of esophageal screening to our portfolio is an important milestone for our Company and one that we think can create significant additional value for our customers. Our WavSTAT® Optical Biopsy platform can be leveraged with additional software applications, and the addition of an esophageal screening function, will allow for a greater return on hardware investment and, more importantly, can extend the level of care that physicians provide to their patients. To accelerate this process, we have engaged Bielderman to manage the data collection from European hospitals that currently have our WavSTAT Optical Biopsy System."

Generally speaking, quality clinical studies are less expensive in Europe. Through its selection of Bielderman, SpectraScience is employing its strategy of obtaining international approval first and marketing its product in Europe while concurrently moving forward with an FDA submission for approval in the United States.

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending for its WavSTAT Optical Biopsy and LUMA® Cervical Imaging Systems. These non-invasive optical biopsy devices are used to diagnose tissue quickly to determine if it is normal, pre-cancerous, or cancerous within seconds. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. As noted above, evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is in process.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically illuminate tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

    SpectraScience, Inc.
    Jim Hitchin, Chief Executive Officer
    (858) 847-0200 x201

    Hayden Communications
    Investor Relations
    Todd Pitcher

SOURCE SpectraScience, Inc.

SOURCE SpectraScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Germany & Austria
2. SpectraScience CEO Jim Hitchin Featured in Interview With The Wall Street Transcript
3. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
4. SpectraScience Strengthens Leadership Team With Four Key Hires
5. Jim Dorst Joins SpectraScience as CFO
6. SpectraScience Appoints the Honorable Tommy Thompson to its Board of Directors
7. CardioGenics Holdings Inc. Engages Gilford Securities As Investment Banker
8. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
9. Healthplace America Engages Robert A. Yungk to Provide Services as Chief Strategy Officer
10. Gentag, Inc. Engages US and UK Firms to Explore Strategic Options
11. MMR Information Systems, Inc. Engages Houlihan Smith
Post Your Comments:
(Date:11/30/2015)... , Dec. 1, 2015  An interventional radiology technique shows ... the preliminary results of a study being presented today at ... North America (RSNA). --> ... for decades by interventional radiologists as a way to stop ... procedure as a means of treating obesity is new. ...
(Date:11/30/2015)... /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today ... to its Board of Directors to replace Dr. ... wealth of experience as co-founder of Resverlogix, with expertise in ... --> --> Dr. Wong remarked, "I am ... Zenith,s long standing expertise in epigenetics and the advanced stage ...
(Date:11/30/2015)... Florida , November 30, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, today announced it will be presenting at ... on December 1, 2015 at 2.30 PM PT. Dr. ... and Strategic Advisor will be giving the presentation and ...
(Date:11/30/2015)... , Nov. 30, 2015  Northwest Biotherapeutics (NASDAQ: ... DCVax® personalized immune therapies for solid tumor cancers, announced ... additional independent director, and the Company welcomes Neil ... in a recent anonymous internet report on NW Bio.  ... Linda Powers stated, "We agree with ...
Breaking Biology Technology:
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):